The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group

Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios

(2010) K. Carlson et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine

(2010) Dennis A. Hanson et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease

(2010) E Terpos et al.   LEUKEMIA

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

(2009) E. Terpos et al.   ANNALS OF ONCOLOGY

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

(2009) M Dimopoulos et al.   LEUKEMIA

Myeloma Bone Disease: Recent Advances in Biology, Diagnosis, and Treatment

(2009) O. Sezer   ONCOLOGIST

Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma

(2008) Martin Kaiser et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The clinical significance of soluble human leukocyte antitgen class-I, ICTP, and RANKL molecules in multiple myeloma patients

(2008) Philipp Schütt et al.   HUMAN IMMUNOLOGY

Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma

(2008) C Jakob et al.   LEUKEMIA

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

(2008) E Terpos et al.   LEUKEMIA

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

(2008) I Breitkreutz et al.   LEUKEMIA

Pathogenesis of myeloma bone disease

(2008) G D Roodman   LEUKEMIA